1.
1
VESTIBULATOR 1.0
A patented therapeutic device invented by Industrial Research
Center of IIT Bombay

2.
22
Agenda
1. Overview
2. Product Info and Details
3. The Problem
4. Current Solution
5. Opportunity
6. Vestibulator™ Product
7. Team
8. Our Strategy
9. Financial Viability
10. Break Even Analysis
11. Investors IRR/ROI
12. Why Us?
13. Roadmap
14. Fund Requirement
15. Awards/Certifications

3.
33
Overview
 Transpact® is a Social Enterprise in Joint research with Industrial
Research Center of IIT Bombay to commercialize innovative and
patented therapeutic device, incubated at SINE (Society for Innovation and
Entrepreneurship), IIT Bombay and CIIE (Center for Innovation
Incubation and Entrepreneurship) IIM Ahmedabad
 Vision: To impact lives of people through
continuous technological interventions and
innovations.
 Mission: To provide innovative, cost-effective
and comprehensive solutions, products and
services with strategic partnerships and
collaborative relationships to help specially
abled people to transcend their barriers.

4.
 170 million children in the world with developmental
disabilities, 14 million in India1
 CP & Autism count for 20% of all disabilities2
 40% of adults above 40 years have some sort Vestibular
dysfunctions leading to dizziness & balance issues.
 Shortage of qualified Physiotherapists and Occupation
therapists (1 in 10,000 Population/Only 50000 in India –
WHO)
44
The Problem
Source of Data
1-Source: AYU .34(1); Jan-Mar 2013 2- CDC-2012

5.
55
Current Solution

6.
66
Opportunity
 Market Size
 The demand for physiotherapy and rehabilitation equipment
currently represents a global market share of approximately $6 billion
 Outpatient rehabilitation is $29.6 billion industry that is expected to grow
7% annually through.
 Target Segment
 Cerebral Palsy and Autism Children
 Vertigo, Accidental strains, Paralysis attack, Post-Surgery rehabilitation
and sports injury.
 Estimated Number of Buyers (India)
 All Hospitals having physiotherapy department – 2,35,000 Hospitals
 Special Children Schools – 2,500
 Physiotherapy Centers – 70,000
 Individuals with CP/Autism (Future version)

7.
77
Vestibulator™- Product Info
 A scientific therapeutic device to stimulate
Vestibular system of Cerebral Palsy children.
 Introducing first time ever prescription in
Physiotherapy
 5X improvement, multiple kids handling
simultaneously and consistency in treatment.
 An instrument for Vestibular checking and
testing.
 Motorized as well as Manual version to serve
the need of rural sector.

8.
88
Product Details
 Vestibulator™  Vestibular + Stimulator
 “Pacemaker” for Vestibular System (Internal GPS system for the body)
 Positioning
 Supine
 Prone
 Sitting
 Quadruped
 kneeling
 standing
 Stimulation
 Forward
 Backward
 Tilting
 Linear
 Gravitational

9.
99
Product Journey
Year 2013
 Academic Research
 Need Identification
 SRCC Project
Year 2014
 Proof of Concept
 SAARTHI School
Year 2015
 Functional Prototype - Alpha
 Patent Filed
Year 2016
 Beta Version
 Clinical Trial/Study

10.
1010
Current Status - 2017
Year 2017
 RTM (Release To Market) Version
 Top 10 Customers – Initial discussions with 3 Hospitals in Mumbai

11.
1111
 Aaliya Baig
 Program Manager responsible for business processes, operation and
regulatory compliances along with co-ordination on product development .
 MBA in HR and MSc from Mumbai University.
 Kamlesh Sawant
 Over 10 years of experience in the areas of Engineering, Consulting, Research
and Development
 Worked on product design projects in Healthcare and Pharma segment
 M.Des Industrial Design from IDC IIT Bombay and B.E. Mechanical
Engineering
 Sanjay Bobade
 A Production Engineer with over 13 years of work experience in design and
fabrication of SPM (special purpose machines), conveyors, Machine tools
 Rajesh Shipurkar
 Over 20 years of experience in Fabrication, Tool and die making
Product Team

12.
1212
Founding Team
 Aslam Khan
 A serial entrepreneur in Information Technology and Healthcare industry with
20 years experience.
 Proven track-record in starting up and growing businesses in global market.
 Engineering graduate with management qualification from IIM Calcutta and
Business education from Harvard Business School, MIT’s Sloan School of
Management, and Said Business School of Oxford University.
 Anis Choudhary
 A passionate social worker, entrepreneur and management guru
 22 years experience in administration, operation and academics.
 MSc, MBA, Mphil from Mumbai University.
 Sudhir Bania
 18 years of rich experience in creative and functional product design.
 Delivered award winning designs for F500 clients - Samsung, GE, Reliance
 Master of Design from IIT Bombay. Associated with NID Ahmedabad, MIT ID
Pune and IIMA.

13.
1313
Board of Advisors
 Prof GG Ray
 Head of IDC-IIT Bombay. Senior Scientist in field of Ergonomics for 40 years.
 President of Indian Society of Ergonomics and Chairman of Bureau of Indian
Standards, Ergonomics section.
 Dr Dhruve Mehta
 Experienced Physiotherapist wit 35 years of experience specializing in
Cerebral Palsy.
 Recipient of Dr. PN Berry’s scholarship for United Kingdom.
 Ms Lavanya Buchwal
 Research Associate and a child nutrition specialist associated with Apollo
polyclinic
 Dr Nikhil Bhandari
 Consulting Pediatrician & Neonatologist and a certified PAL from American
Academy of Pediatrics

14.
1414
Our Strategy
 International Patent of Vestibulator™
 Vestibulator™ built to meet consumer and business need
 Vestibulator™ Standard – Motorized version for Center/Hospital
 Vestibulator™ Professional – For corporate Use
 Vestibulator™ Light – For Home Use
 Vestibulator™ Easy – Manually operated for Rural sector
 Pricing Model - Outright, Rent, Pay-per-Use
 Integrated Software for patient data analytics
 An echo system with Corporate-NGO partnership under CSR
 Continue research and product enhancement by IRCC of IIT
Bombay
 Certification by CLAA/CE (India), MHRA (UK) and FDA (USA)
 Manufacturing by ISO 13485 certified company
 Approval of Ministry of Social Justice, IAPA

15.
1515
Financial Viability
 Primarily there are 3 revenue streams
1. Product Sales

Vestibulator™ Standard – $11,500/-

Vestibulator™ Professional – $15,000/-
1. Annual Maintenance Contract
2. Upgrade from Vestibulator™ 1.0 to 2.0 – Additional revenue
3. Accessories Sale, Training and Services
 We expect the project to breakeven in 3rd
Year and stable rise
in the business and revenue from that point.
 Initial 1 year will be entirely invested in Packaging, Marketing,
Business Development and Channel Partnership

16.
1616
Pricing Viability for Customer
850000
170000
680000
48
17907
0.12
VESTIBULATOR® COST
PERSONAL CONTRIBUTION
LOAN ASKED
PERIOD IN MONTHS
P.A + INST/ MONTH
INT.ON LOAN AMOUNT
OUTGOING (X) 1ST YEAR 2ND YEAR 3RD YEAR 4TH YEAR
EMI ON LOAN VALUE 17907 17907 17907 17907
ELECTRICITY /MONTH 1260 1620 2760 3360
CONSUMABLE/MONTH 5040 6480 10350 15120
DEPRECIATION/MONTH 17708 17708 17708 17708
MAINTENANCE/REPAIR 7083 7083 7083 7083
SALARY/MONTH 96000 139500 179250 247500
TOTAL EXPENSE/MONTH 144999 190299 235059 308679
INCOMING (Y)
PHYSIO PATIENT/DAY 10 12 15 18
PATIENT/MONTH (30 days) 300 360 450 540
FEES/PATIENT 400 450 450 500
INCOME/M A 120000 162000 202500 270000
CP PATIENT/DAY 4 6 8 10
PATIENT/MONTH (30 days) 120 180 240 300
FEES/PATIENT 600 650 650 750
INCOME/M B 72000 117000 156000 225000
TOTAL INC A+B 192000 279000 358500 495000
PROFIT/M(X-Y) 47001 88701 123441 186321
PROFIT / YEAR 564016 1064416 1481296 2235856
* Figures in INR
* Cost Rs. 8,50,000 = $ 11,500

17.
1717
Project Break Even
 The estimated unit cost of manufacturing the Vestibulator™ $4,000 and average sales cost of
unit is considered as $11,500.
 Number of units planned to be manufactured in Year 6 is 2000.
 Administrative expense includes salaries of personnel and travelling expenses.
** Figures in USD
Particulars Year 1 Year 2 Year 3 Year 4 Year 5
Vestibulator™ Unit Sales 0 100 500 1000 2000
Income (Sales Revenue) 0 1,150,000 5,750,000 11,500,000 23,000,000
Cost of Sales 400,000 2,000,000 4,000,000 8,000,000 8,000,000
Gross Margin -400,000 -850,000 1,750,000 3,500,000 15,000,000
Administrative Expenses 200,000 300,000 400,000 400,000 400,000
Sales/Marketing Expenses 400,000 400,000 400,000 600,000 1,000,000
Research & Development 0 200,000 200,000 300,000 500,000
Total Operating Expenses 600,000 900,000 1,000,000 1,300,000 1,900,000
Net Profit -1,000,000 -1,750,000 750,000 2,200,000 13,100,000

18.
1818
Returns on Investment
• The revenue stream to investor is as stated above
• The project will generate positive cash flow from year 3
• The project IRR in our structure for investor stands at 12.5% for investment of $3 (2.75) million for 5
years
Particulars Year 1 Year 2 Year 3 Year 4 Year 5
Net Profit -1,000,000 -1,750,000 750,000 2,200,000 13,100,000
Returns to Investors (30%) 0 0 225,000 660,000 3,930,000
Total Returns (cummulative) 0 0 225,000 885,000 4,815,000
Initial Investment (2,750,000)
Returns in Year 1 0
Returns in Year 2 0
Returns in Year 3 225,000
Returns in Year 4 660,000
Returns in Year 5 3,930,000
IRR 12.51%

19.
1919
Why Us?
 Vestibulator™ is unique and innovative invention in therapeutics
instrument segment.
 The device is easy and safe to use, durable and light weight for
portability.
 Certification from authorized body for safety and quality.
 Collaboration with “SAARTHI School for Special Children” for quality
assurance and testing of instrument.
 Professional industrial design team with proven track record driving the
product.
 Highly Experienced expert Physiotherapists, Ergonomics and Nutrition
researcher on board.

20.
08/31/17 2020
Roadmap
03/2019
Vestibulator
2.0
(Manual)
EXIT
(After 5
years)
Global
Customers
12/2019
Guerilla
Marketing
02/2017
Series “A” Funding
$2,000,000 for 17.5%
$12-15 Million Valuation
Seed Fund
$1,000,000; for 12.5%
$8-10 Million PMV
Prototype
Beta v1
10/2016
QA/
Clinical
Trial/CE
08/2017
DEALERS/
CUSTOME
R
12/2018
Vestibulator1.0
10 Customers
12/2017
FIRST
Batch
Production
06/2018

21.
2121
Financial Requirements
Currently Seeking $1,000,000 Capital
• Expected value of the Enterprise/Project is estimated at $8 Million pre-
money valuation
• Targeted Closing Date: 31st
August 2017
• $100,000: Beta, CE Certification and QA cost
• $400,000: Advance for manufacturing cost
• $300,000: Marketing and Biz Dev cost for analysis/globalization
• $100,000: Founders working full-time marketing/launching the product
• $100,000: Infrastructure, Legal, Compliance and Misc. expenses
Funds Utilization of SEED

22.
2222
Awards/Certifications

23.
2323
Thank You
Contact US:
Aslam Khan Anis
Choudhary
aslam@transpact.in anis@transpact.in
(+91) 987 037 7674 (+91) 922 4763158
http://www.transpact.in